Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib-Report of Three Cases

Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib-Report of Three Cases

Pazopanib is a potent multi-kinase inhibitor that hinders angiogenesis and blocks tumor growth. It has been approved for the treatment of metastatic renal cell carcinoma (mRCC) and advanced soft tissue sarcoma. There is emerging evidence that bleeding is a common adverse effect of pazopanib and othe...

Full description

Saved in:
Bibliographic Details
Main Authors: Erofili Papadopoulou (Author), Emmanouil Vardas (Author), Styliani Tziveleka (Author), Maria Georgaki (Author), Maria Kouri (Author), Konstantinos Katoumas (Author), Evangelia Piperi (Author), Nikolaos G. Nikitakis (Author)
Format: Book
Published: MDPI AG, 2022-12-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items